Previous 10 | Next 10 |
Alongside its Q3 results last night, Ironwood Pharmaceuticals (IRWD) announced the appointment of Alexander Denner to the board, effective next week.Dr. Denner is the founder and CIO at Sarissa Capital Management.Board Chair Julie McHugh: "We believe [Denner's] wealth of knowledge will be inv...
Ironwood Pharmaceuticals (IRWD): Q3 Non-GAAP EPS of $0.23 beats by $0.08; GAAP EPS of $0.21 beats by $0.08.Revenue of $103.47M (-21.1% Y/Y) beats by $7.39M.FY20 guidance: Total Revenue of $370M–$385M from previous guidance of $360M–$380M vs consensus of $368.2M ; Adjusted EBITDA...
– U.S. LINZESS ® (linaclotide) net sales increased 10% year-over-year to $241 million, as reported by AbbVie Inc. (AbbVie) – – U.S. LINZESS collaboration revenue to Ironwood increased 18% year-over-year to $100 million, resulting in 3Q 2020 ...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Alexander Denner, Ph.D., to its Board of Directors, effective November 9, 2020. Dr. Denner is the founding partner and chief investment officer of Sarissa Capital Management LP. With the appointment of ...
[[AAXN]], [[ACLS]], [[ADT]], [[AGO]], [[AIG]], [[AINV]], [[ALRM]], [[ALTR]], [[AMCR]], [[AMH]], [[AMN]], [[ANGI]], [[APPN]], [[ATGE]], [[ATRC]], [[AVLR]], [[AYX]], [[AZPN]], [[BFAM]], [[BGS]], [[BHF]], [[BIGC]], [[BILL]], [[BKNG]], [[BLDP]], [[BMRN]], [[BNFT]], [[CABO]], [[CARG]], [[CDAY]], [...
Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q3 earnings results on Thursday, November 5th, after market close.The consensus EPS Estimate is $0.15 (-62.5% Y/Y) and the consensus Revenue Estimate is $96.08M (-26.8% Y/Y).Over the last 2 years, IRWD has beaten EPS estimates 63...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2020 investor update conference call and webcast at 4:30 p.m. Eastern Time on Thursday, November 5, 2020. Individuals interested in participating in the call should dial (833) 350-1432 (U.S....
Results from phase 2 STRONG-SCD study using olinciguat for the treatment of patients with sickle cell disease expected before the end of 2020. The global sickle cell disease market is expected to reach $5.5 billion by 2023. IW-6463 is being used to target patients with Alzheimer's...
Wells Fargo downgrades Ironwood Pharmaceuticals (IRWD) to Equal-Weight from Overweight and lowers the price target to $9 from $14, citing the latest pipeline miss in IW-3718.The company yesterday announced that it will terminate development of IW-3718 for refractory gastro...
Ambow Education (AMBO) -17%.Oxbridge Re (OXBR) -13%.The Peck Company (PECK) -12%.Ironwood Pharmaceuticals (IRWD) -12% on terminating development of IW-3718 for refractory gastroesophageal reflux disease.Urban One (UONE) -11%.Professional Diversity Network (IPDN) -10%....
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...